Peptide dossier, updated Nov 1, 2026
Selank
A synthetic seven-amino-acid peptide that papers describe as an analog of tuftsin. FDA lists it as selank acetate (TP-7). It has no approved use in the United States. A Russian drug-reference site lists it as a registered nasal drop. The human literature we found is small clinical reports from Russian journals. FDA says it lacks important safety information. This page lays out what each source actually says.
See all 10 verified records for Selank on the Records page
In plain terms
Approved for: Nothing in the United States. A Russian drug-reference site (RLS) lists Selank 0.15% nasal drops under a Russian registration number, held by the company Peptogen, for anxiety states and the prevention and treatment of stress disorders. We did not open Russia’s state register itself.
What it is: A synthetic seven-amino-acid peptide. Papers describe it as an analog of tuftsin, a natural peptide.
What it is said to do, and by whom:
- Researchers in Russia: a 2014 report on 60 patients with anxiety-related disorders says selank showed a pronounced anxiolytic effect and a mild nootropic effect, compared with the sedative phenazepam. A 2015 report says adding selank to phenazepam reduced the sedative’s side effects.
- Researchers: rat and mouse studies report effects on stress, memory, alcohol and morphine withdrawal, and gene activity.
- We did not collect sellers’ claims for this compound.
How strong the evidence is: Thin. The human reports are small and from Russian journals, and the abstracts do not describe blinding. We found no registered trial and no study from outside that literature.
FDA review
FDA’s safety-risk page (content current Apr 22, 2026) is the one FDA document on selank that we read.
What the page says
- It lists “selank acetate (TP-7)” in the table of bulk drug substances nominated but withdrawn, previously in category 2 under the interim policies.
- It says compounded drugs containing it may pose risk for immunogenicity for certain routes, because of aggregation and peptide-related impurities.
- It says FDA lacks important information regarding any safety issues raised by selank acetate administered to humans.
What we did not find
- We found no FDA briefing document, advisory committee review or press release specific to selank.
- ClinicalTrials.gov’s search for selank returned two records. Neither is a selank study; both test brain stimulation.
Published research
PubMed returns 68 results for selank in the title or abstract as of Nov 1, 2026. Most are rat and mouse studies in Russian journals, many with English abstracts.
What the papers show
- Anxiety disorders, 2014. 60 patients with phobic-anxiety and somatoform disorders, selank compared with phenazepam. The abstract reports pronounced anxiolytic and mild nootropic effects, and an anxiolytic effect lasting a week after the last dose. It does not describe blinding or group sizes. Zh Nevrol Psikhiatr PubMed
- Anxiety disorders, 2015. 30 patients on phenazepam alone versus 40 on selank plus phenazepam. The abstract reports fewer sedative side effects in the combined group. Zh Nevrol Psikhiatr PubMed
- Rats, 2017-2022. Studies of stress, alcohol, morphine withdrawal and memory, for example a 2022 paper on morphine withdrawal signs. Bull Exp Biol Med PubMed
- Seized products, 2020. A study of research peptides found in seized pharmaceutical preparations. We read the title only. Drug Test Anal PubMed
Read with care
- Both human reports compare against an active drug, not a placebo, and we read abstracts only.
- Rat results do not show an effect in people.
- We did not check funding or author affiliations.
FDA warning letters
We found one FDA warning letter that names selank. It is addressed to a compounding pharmacy and is not a finding about selank’s safety. This rests on web searches.
| Recipient | Date | Letter | What it says |
|---|---|---|---|
| Tailor Made Compounding LLC, a compounding pharmacy | Apr 1, 2020 | Warning letter 594743 | FDA says an inspection found the firm compounding with a list of 22 bulk substances that includes Selank, and that drugs made from them were not eligible for the section 503A exemptions because none is covered by a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A bulks list. The letter also says that Selank and a group of other listed substances had not been nominated for FDA to evaluate. We read the letter text. FDA’s page now lists selank acetate as nominated and withdrawn. |
A warning letter is FDA’s statement about one firm’s conduct on one date. It is not a finding about the substance. FDA’s list of letters cannot be searched by peptide, so other letters could exist that we did not find.
Timeline
Newest first. Every entry links to the document it comes from.
- Government or registry record
- Journal
- Oct 30, 2026RegulatoryHHS publishes draft policy pausing enforcement on six peptides; Selank is not one of them
The draft policy’s appendix names six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500. The policy is a draft and not FDA approval. We read the appendix through a text extraction.
- July 23–24, 2026RegulatoryFDA advisory committee meets on seven peptides; Selank is not among them
The committee recommended six of the seven, all nonbinding. FDA’s notice of the meeting does not list Selank.
- Apr 22, 2026RegulatoryFDA’s safety-risk page lists Selank
FDA lists “selank acetate (TP-7)” among nominated-but-withdrawn substances, citing immunogenicity risk and a lack of important safety information.
- Jul 15, 2025RussiaRussian register and drug-reference page list Selank nasal drops as registered
Russia’s State Register of Medicines lists Selank nasal drops, held by Peptogen, registered Jul 15, 2025. The commercial RLS page shows registration ЛП-010951 and the same holder. We read the register’s results table, not the full registration card.
- Apr 1, 2020EnforcementFDA warning letter to a compounding pharmacy names Selank among 22 substances
The letter says drugs the firm compounded from these bulk substances were not eligible for the 503A exemptions.
Still not covered
Left off rather than guessed:
- HHS policy: we read the draft policy appendix through a text extraction, not as the original PDF layout. It names six covered peptides and not selank.
- FDA review: we found no FDA briefing document or advisory committee evaluation for selank. FDA’s notice for the July meeting does not name it, so the safety-risk page entry is the only FDA statement on it that we read.
- Status in Russia: we searched Russia’s State Register of Medicines (GRLS) and found Selank nasal drops, held by Peptogen, registered Jul 15, 2025. We read the register’s results table. We did not open the full registration card, so we have not read the approved indications or the current-validity statement.
- The Russian clinical literature: abstracts only; we cannot say how the trials were designed.
- Drugs@FDA: we searched openFDA’s copy of the Drugs@FDA data by active ingredient and found no application. FDA’s own Drugs@FDA site could not be searched from our tools.
- Patents and SEC filings: not researched for this dossier.
- Seller claims and independent lab reports: how gray-market product is marketed versus what testing finds. We have not collected testing data.
- Unread items: full text of most papers; EU and other non-US regulators and registries; WADA lists for years other than 2026; FDA warning letters beyond those listed, which rest on web searches.